Shares of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $6.25.
Several analysts have recently weighed in on CPRX shares. Zacks Investment Research downgraded Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. BidaskClub downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 7th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 10th. SunTrust Banks set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 31st. Finally, Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, November 1st.
Several hedge funds have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $111,000. New York State Common Retirement Fund purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $114,000. State of Wisconsin Investment Board purchased a new position in Catalyst Pharmaceuticals in the second quarter valued at about $149,000. SG Americas Securities LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at about $144,000. Finally, The Manufacturers Life Insurance Company grew its stake in Catalyst Pharmaceuticals by 1,861.3% in the second quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 59,896 shares during the last quarter. Hedge funds and other institutional investors own 34.75% of the company’s stock.
Shares of Catalyst Pharmaceuticals (CPRX) opened at $3.91 on Monday. Catalyst Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $4.51. The firm has a market capitalization of $400.67, a price-to-earnings ratio of -18.62 and a beta of 1.68.
COPYRIGHT VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://transcriptdaily.com/2018/01/01/catalyst-pharmaceuticals-inc-cprx-given-average-rating-of-buy-by-brokerages.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.